{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/whitlow-staphylococcal-herpetic/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"7c70fe97-728d-5bc4-94c2-1996b37ee0f9","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 617b94ac-7c5d-4169-b1f0-0c3c7324fefe --><h2>Changes</h2><!-- end field 617b94ac-7c5d-4169-b1f0-0c3c7324fefe -->","summary":null,"htmlStringContent":"<!-- begin item 14e629d1-7f7c-4522-be1b-b4ab59243112 --><!-- begin field 0505728d-c740-47a4-82fc-190394eb8125 --><p><strong>January 2021 </strong>— minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update.</p><!-- end field 0505728d-c740-47a4-82fc-190394eb8125 --><!-- end item 14e629d1-7f7c-4522-be1b-b4ab59243112 -->","topic":{"id":"ac1c1826-f21a-5abd-8e92-1e2db8ea28ea","topicId":"f989f159-ab30-4d16-b9df-b534a9fd4192","topicName":"Whitlow (staphylococcal and herpetic)","slug":"whitlow-staphylococcal-herpetic","lastRevised":"Last revised in January 2021","chapters":[{"id":"8442fc1d-a788-50ac-a15a-9c2c91e8589b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"895f3b40-8720-5843-8910-fe1b288857a8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7e4ec3c7-b080-5717-b1c3-0003acba46e5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7c70fe97-728d-5bc4-94c2-1996b37ee0f9","slug":"changes","fullItemName":"Changes"},{"id":"4889bd92-0b32-558d-8390-80d27fbcce73","slug":"update","fullItemName":"Update"}]},{"id":"1a79ca57-c8cc-5044-ac68-5d220bab1460","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"684fde23-e839-56ff-8b7f-8e6863b2c42d","slug":"goals","fullItemName":"Goals"},{"id":"97b35971-df6d-5ecb-a631-dfcf580e1fa9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12181a78-1b8d-58b4-884a-8930d15cf654","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"521ae353-eea7-5e2f-bd0e-b292540b72eb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"87054726-2905-5ac0-b369-92e5fd68a177","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2b6dffce-588f-532a-9776-7e3ff32005ee","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"2d957194-aa56-5cb7-98aa-cb3d8f988743","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f0191f08-fb2e-5c5b-957c-8a190d5b4539","slug":"definition","fullItemName":"Definition"},{"id":"b8b2a1f1-fbc7-5b8f-a5c4-c0e9409d566f","slug":"causes","fullItemName":"Causes"},{"id":"c7287d38-e377-5d65-9c4f-3201369e0213","slug":"prevalence","fullItemName":"Prevalence"},{"id":"adc749af-b4d0-50c9-9996-b470b8f76613","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d632b72f-6e73-58ee-9d8d-21b6101f6394","slug":"prognosis","fullItemName":"Prognosis"},{"id":"faed0075-1878-5f17-abc9-9316eaa064e7","slug":"complications","fullItemName":"Complications"}]},{"id":"96e4a200-e348-5fab-89e2-f0ba789b7b72","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"910097a7-71be-5c13-949e-0be7c045df35","slug":"diagnosis-of-whitlow","fullItemName":"Diagnosis of whitlow"},{"id":"6f468174-fafe-579c-90f9-500f22e70e17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"8ac8a269-e748-5e7e-9b74-8fb5661d1ae5","fullItemName":"Management","slug":"management","subChapters":[{"id":"ac7fabf7-d7b7-5fb2-a0a6-1d28e040e2c8","slug":"staphylococcal-whitlow","fullItemName":"Scenario: Staphylococcal whitlow"},{"id":"bde8ed40-6fd8-505e-86bb-d75eac34743f","slug":"herpetic-whitlow","fullItemName":"Scenario: Herpetic whitlow"}]},{"id":"5d7afad5-ae43-5c2e-8ecf-6df00603ca01","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3b006b-c4df-5e15-aee8-5ac6c019923f","slug":"aciclovir","fullItemName":"Aciclovir"},{"id":"46185de6-35ef-5e34-a1fd-e0d1463c538e","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"2a50e932-9f92-5a94-a8e5-aab1ee400b9d","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"0ad07f56-519a-59d6-90bc-6b6d6081e6ab","slug":"flucloxacillin","fullItemName":"Flucloxacillin"}]},{"id":"98ea0d83-9b18-58b4-aa73-7a50d72e15ba","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dd77db6-a4e1-5304-8a06-196e7628f612","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0191f79d-0e03-554c-b0bd-4b592d452f4a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3e95c155-472c-52d0-9098-a797cec2ad27","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f39c5716-7472-576a-be8f-7d705a0dc4dd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"73c24405-a40a-51ba-ac01-8dd957f7c657","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7005b3b9-63e2-5222-840e-73155dac338e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"18dd81bb-78d7-57f1-9fc9-24aa775b3c9d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7e4ec3c7-b080-5717-b1c3-0003acba46e5","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"8a5318ef-61b4-5f8c-b608-91ed89236f17","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 4ad440c5-f731-4cf7-8245-e622da449a9f --><h3>Previous changes</h3><!-- end field 4ad440c5-f731-4cf7-8245-e622da449a9f -->","summary":null,"htmlStringContent":"<!-- begin item 5002aed9-0562-4ce7-a447-9eba731c2908 --><!-- begin field 93a4130f-bcc0-40bb-b19a-a2e338f95693 --><p><strong>December 2016 </strong>— minor update. The dose of clarithromycin for people with severe renal impairment has been clarified, in line with the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2016</a>].</p><p><strong>March to April 2016</strong> — reviewed. A literature search was conducted in March 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to the recommendations have been made.</p><p><strong>July 2015</strong> — minor update. The prescribing information sections on erythromycin and clarithromycin have been clarified.</p><p><strong>F</strong><strong>ebruary 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>July 2011</strong> — minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency. Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>May 2011</strong> — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>April 2011</strong> — minor update. Change to recommendation regarding need for additional contraception during or after a course of antibiotics - additional contraception is no longer required when using antibiotics that are not enzyme inducers with combined hormonal methods for durations of 3 weeks or less. Issued in June 2011</p><p><strong>November 2010 to March 2011</strong> — CKS topic revised. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. This CKS topic replaces the former topic on Boils and paronychia, which included the management of staphylococcal whitlow. There are now separate CKS topics on Boils, carbuncles, and staphylococcal carriage and Paronychia - acute. This topic now includes the management of herpetic whitlow.</p><p><strong>July 2007</strong> — Oilatum Plus discontinued. Minor change to the text made and prescriptions removed. Issued in August 2007.</p><p><strong>December 2006 to March 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>October 2006</strong> — minor update. Analgesia prescriptions updated because new doses of ibuprofen for children are recommended by the British National Formulary. Issued in October 2006.</p><p><strong>October 2005</strong> — minor technical update. Issued in November 2005.</p><p><strong>September 2003</strong> — written. Validated in December 2003 and issued in February 2004.</p><!-- end field 93a4130f-bcc0-40bb-b19a-a2e338f95693 --><!-- end item 5002aed9-0562-4ce7-a447-9eba731c2908 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}